Private Advisor Group LLC Lowers Stake in Novo Nordisk A/S (NVO)

Private Advisor Group LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 17.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 11,629 shares of the company’s stock after selling 2,436 shares during the quarter. Private Advisor Group LLC’s holdings in Novo Nordisk A/S were worth $491,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Freestone Capital Holdings LLC boosted its position in shares of Novo Nordisk A/S by 101.4% during the 2nd quarter. Freestone Capital Holdings LLC now owns 188,406 shares of the company’s stock valued at $8,081,000 after acquiring an additional 94,877 shares during the last quarter. Atlantic Trust Group LLC bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $2,909,000. Synovus Financial Corp boosted its position in shares of Novo Nordisk A/S by 35.7% during the 2nd quarter. Synovus Financial Corp now owns 13,465 shares of the company’s stock valued at $577,000 after acquiring an additional 3,541 shares during the last quarter. Autus Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 1.0% during the 2nd quarter. Autus Asset Management LLC now owns 157,477 shares of the company’s stock valued at $6,754,000 after acquiring an additional 1,603 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $275,000. Hedge funds and other institutional investors own 6.01% of the company’s stock.

Shares of Novo Nordisk A/S (NYSE:NVO) opened at 48.19 on Friday. The company’s 50-day moving average price is $45.61 and its 200 day moving average price is $40.85. Novo Nordisk A/S has a 12-month low of $30.89 and a 12-month high of $48.88. The stock has a market cap of $119.52 billion, a price-to-earnings ratio of 19.47 and a beta of 0.60.

The business also recently disclosed an annual dividend, which was paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st were paid a dividend of $0.336 per share. The ex-dividend date was Friday, August 18th. This represents a yield of 1.07%. This is a positive change from Novo Nordisk A/S’s previous annual dividend of $0.33. Novo Nordisk A/S’s payout ratio is 36.44%.

TRADEMARK VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/17/private-advisor-group-llc-lowers-stake-in-novo-nordisk-as-nvo.html.

NVO has been the topic of several recent research reports. BidaskClub upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Zacks Investment Research lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Finally, Bank of America Corporation upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $56.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply